The plaintiffs ingested the defendants’ allegedly contaminated Valsartan product. The plaintiffs alleged that the active ingredients supplied by this company contained certain nitrosamine compounds, and that exposure to those compounds increases the risk of being diagnosed with cancer.

Each defendant subcontracted the manufacture and supply of the drug’s active ingredients to a company in China. The defendant pharmaceutical companies manufactured and distributed the bioequivalent of Valsartan. The plaintiffs were prescribed Valsartan, a drug indicated to treat high blood pressure.

In Palmer, the court was asked to certify a proposed class action relating to an allegedly contaminated pharmaceutical drug. Teva Canada Ltd, the Ontario Superior Court of Justice denied certification, under the Class Proceedings Act, 1992 (the Act), of a proposed class action for product liability on the basis that a plaintiff who may have suffered an increased risk of harm does not have a legally viable negligence claim if that harm has not yet materialized.

Casino rama labour dispute